Saturday 17 October 2026 Export IMDX’s income statement to Excel — free account

Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, up 115.6% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3.33% and free cash flow fell 54.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

3.01 0.05 −1.63%

Follow IMDX

Alert me

Market cap: $100.1M
P/E: 0.0×
Fwd P/E: −6.4×
Dividend yield: —
F-score: 3/9
Altman Z: −25.63
Beneish M: −7.73
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 5.69

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	2	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 72.19%

Capital & Financial Ratios $m

Market Cap 100.14

Revenue 1.67

Net Income (49.36)

Free Cash Flow (31.00)

Net Debt (17.57)

Current Ratio 2.00

Debt/Equity (0.04)

P/E ratio 0.00

Fwd P/E (6.43)

P/S ratio 66.24

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 45.18%

Next Y EPS Growth 4.82%

Next Y revenue growth (76.33%)

Next 5Y EPS Growth 27.84%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 69.33%

10-year low 10-year high

EV/Sales against its own 10 years 68.43%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	9	9	12	18
Receivables	0	2	1	0
Inventory	—	0	0	0
Other	0	0	—	—
	11	12	15	21

	2023	2024	2025	Q'26
Payables	1	2	3	2
ST’ Debt	—	—	—	—
Other	2	0	0	1
	7	7	12	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	27.24%	61.76%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	2	1	0	1	4
’24	0	0	0	1	2
’23	0	0	0	0	2
’22	0	0	0	0	1
’21	1	2	1	(2)	2

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(9)	—	—	—
’25	(6)	(6)	(5)	(6)	(22)
’24	(4)	(6)	(6)	(5)	(21)
’23	(8)	(7)	(4)	(4)	(23)
’22	(13)	(11)	(11)	(10)	(46)
’21	(10)	(8)	(11)	(7)	(36)
’20	(7)	(7)	(6)	(6)	(26)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(10)	—	—	—
’25	(6)	(7)	(6)	(7)	(25)
’24	(4)	(6)	(6)	(6)	(21)
’23	(8)	(7)	(4)	(5)	(23)
’22	(15)	(12)	(12)	(10)	(50)
’21	(11)	(9)	(11)	(7)	(38)
’20	(7)	(7)	(7)	(6)	(27)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.12)	(0.31)	—	—	—
’25	(0.26)	(0.30)	(0.34)	(0.72)	(1.65)
’24	(1.13)	(0.36)	(0.98)	(1.93)	(4.66)
’23	0.40	(1.07)	(0.81)	(2.32)	(3.75)
’22	(2.20)	(1.40)	(1.60)	(7.89)	(13.20)
’21	(1.00)	(2.40)	(3.00)	(7.80)	(14.40)
’20	(2.60)	(2.80)	(2.00)	(1.80)	(9.20)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	49.00	72.00	22.00	26.80	23.00	40.30	4.84	2.08	1.97	1.92	Analyst estimates 2026–2028 Powerpack
	High	204.80	157.08	96.00	138.40	70.20	131.40	45.28	10.00	3.82	8.51
People
People	Employees	15	16	12	33	51	110	76	46	49	58
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.02	0.02	0.01	0.03	0.04	0.07
Income, $m
Income, $m	Revenue	—	—	—	—	1	2	1	2	2	4
	Gross margin, %	0.00	0.00	0.00	0.00	(52.55)	64.60	(1.88)	27.48	39.34	56.67
	EBT	(11)	(19)	(16)	(22)	(31)	(53)	(19)	(25)	(61)	(50)
	EBT margin, %	0.00	0.00	0.00	0.00	(2,564.64)	(2,405.41)	(1,942.80)	(1,653.69)	(3,225.04)	(1,238.52)
	Net income	(11)	(19)	(16)	(22)	(30)	(64)	(73)	(28)	(61)	(50)
	Depreciation	0	1	1	0	1	4	24	2	2	2
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.37	0.49	0.17	0.20	0.14	0.13
	Earnings	(8.40)	(12.80)	(8.40)	(8.80)	(9.20)	(14.40)	(13.20)	(3.75)	(4.66)	(1.65)
	Cash flow	(5.67)	(8.87)	(6.16)	(7.69)	(7.94)	(8.08)	(8.23)	(3.05)	(1.58)	(0.73)
	Capex	(0.08)	(0.06)	(0.02)	(0.36)	(0.37)	(0.51)	(0.78)	0.01	(0.04)	(0.10)
	Free cash flow	(5.75)	(8.93)	(6.17)	(8.04)	(8.31)	(8.59)	(9.01)	(3.04)	(1.62)	(0.83)
	Book value	7.43	2.92	1.81	12.02	10.23	14.67	6.19	2.68	(0.94)	(1.03)
	Shares, m	1	2	2	3	3	4	6	8	13	30
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	128.69	87.79	39.90	16.80	16.54	56.37
	P/B	—	—	—	—	4.67	2.96	1.11	1.23	0.00	0.00
	EV/Sales	—	—	—	—	123.51	74.00	21.64	12.09	33.26	53.75
	EV/FCF	—	—	—	—	(5.52)	(4.26)	(0.42)	(0.76)	(2.95)	(8.59)
Cash, $m
Cash, $m	Operating cash flow	(8)	(13)	(12)	(20)	(26)	(36)	(46)	(23)	(21)	(22)
	Capex	0	0	0	(1)	(1)	(2)	(4)	0	(1)	(3)
	Free cash flow	(8)	(13)	(12)	(21)	(27)	(38)	(50)	(23)	(21)	(25)
Balance, $m
Balance, $m	Working capital	8	4	3	19	0	25	13	4	4	3
	Total debt	0	1	1	2	2	4	3	—	40	45
	Net debt	(12)	(7)	(8)	(21)	(6)	(30)	(18)	(9)	31	33
	Shareholders’ equity	10	4	3	31	33	65	34	20	(12)	(31)
Returns, %
Returns, %	ROA	(82.18)	(157.12)	(159.66)	(90.84)	(62.83)	(59.63)	(56.55)	(32.83)	(110.32)	(165.10)
	ROIC	0.00	0.00	0.00	(135.05)	(68.34)	(96.18)	(67.78)	(142.35)	(199.01)	(2,334.00)
	ROE	(110.14)	(271.64)	(402.61)	(130.91)	(93.07)	(129.88)	(147.57)	(104.91)	(1,480.67)	229.65

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BDSX Biodesix, Inc.	$260.7M	— (loss-making)	— (loss-making)	+34.18% (above 0%: growing)	n/m	+72.75% (above 0%: growing)	82.06%	(20.06%)	Compare
XGN Exagen Inc.	$207.4M	— (loss-making)	— (loss-making)	+15.92% (above 0%: growing)	n/m	+211.34% (above 0%: growing)	61.27%	(8.64%)	Compare
BNR Burning Rock Biotech Limited Sponsored ADR	$137.1M	— (loss-making)	11.1×	−4.22% (below 0%: shrinking)	n/m	+46.01% (above 0%: growing)	72.58%	(13.36%)	Compare
MDXHF MedX Health Corp.	$103.2M	— (loss-making)	— (loss-making)	+33.59% (above 0%: growing)	n/m	+41.60% (above 0%: growing)	37.19%	(1,027.95%)	Compare
IMDX Insight Molecular Diagnostics Inc.	$100.1M	— (loss-making)	— (loss-making)	−53.86% (below 0%: shrinking)	n/m	−54.02% (below 0%: shrinking)	65.69%	(4,770.71%)
QUCY Quantum Cyber N.V	$95.1M	— (loss-making)	— (loss-making)	+11.12% (above 0%: growing)	n/m	+26.73% (above 0%: growing)	62.71%	0.00%	Compare
MDXH MDxHealth SA	$57.6M	— (loss-making)	— (loss-making)	+12.01% (above 0%: growing)	n/m	−200.20% (below 0%: shrinking)	65.75%	(18.74%)	Compare
MBAI MBody AI Ltd.	$47.4M	— (loss-making)	—	—	n/m	+122.08% (above 0%: growing)	0.00%	0.00%	Compare
PRPO Precipio, Inc.	$40.4M	— (loss-making)	15.4×	+24.18% (above 0%: growing)	n/m	+79.59% (above 0%: growing)	44.67%	(8.53%)	Compare
Median of peers	$99.1M	—	—	+15.92%	—	+59.38%	61.99%	(11.00%)

All 52 Diagnostics & Research stocks →